


DETERMINER LE PRONOSTIC DANS LES AMYLOSES CARDIAQUES AL : DEUX SCORES

European Staging	Tropo T HS + NTproBNP	HR(95%IC)
Stade 1	NTproBNP <332 ng/l TnT HS <50	REF
Stade 2	NTproBNP >332 ng/l OU TnT HS >50ng/L	2.6 (1.9-3.5)
Stade 3A	NTproBNP >332 (<8500) ET TnT HS >50ngl	4.9 (3.6-6.8)
Stade 3B	NTproBNP >8500 ng/l et cTnT HS >50ng/l	11.1 (8.1-15.4)



[A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.](#) Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, Basset M, Hawkins P, Merlini G, Wechalekar AD. *Blood*. 2015 Jul 30;126(5):612-5. doi: 10.1182/blood-2015-01-620302. Epub 2015 May 18. PMID: 25987656

Correspondance entre European Staging et MACS

Mondor Amyloidosis Cardiaque Staging (MACS)	Tropo T HS + NTproBNP Bilirubine conjuguée	HR(95%IC)
Stage 1 (MACS1)	TnT HS ≤107 ng/mL ET NTproBNP ≤ 3867 ng/L	-----
Stage 2 (MACS2)	TnT HS ≤107 ng/mL ET NTproBNP > 3867 ng/L	2.59[1.53-4..37]
Stage 3 (MACS3)	TnT HS > 107 ng/mL ET Bili conjuguée ≤ 4 mmol/L	4.48[2.53-7.91]
Stage 4 (MACS4)	TnT HS > 107 ng/mL ET Bili conjuguée > 4 mmol/L	8.46[4.98-4.36]



Réseau
Amylose



HEART'S

Healthcare European Amyloidosis
Research Translation and strategy

[Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.](#) Zaroui A, Kharoubi M, Gounot R, Oghina S, Degoutte C, Bezard M, Galat A, Guendouz S, Roulin L, Audard V, Leroy V, Teiger E, Poullot E, Molinier-Frenkel V, Le Bras F, Belhadj K, Bastard JP, Fellahi S, Shourick J, Lemonier F, **Damy T**. *ESC Heart Fail*. 2024 Mar 5. doi: 10.1002/ehf2.14671. Online ahead of print. PMID: 3844409